Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
Heppt MV, Siepmann T, Engel J, Schubert-Fritschle G, Eckel R, Mirlach L, Kirchner T, Jung A, Gesierich A, Ruzicka T, Flaig MJ, Berking C (2017)
Publication Type: Journal article
Publication year: 2017
Journal
Book Volume: 17
Pages Range: 536-
Article Number: 536
Journal Issue: 1
DOI: 10.1186/s12885-017-3529-5
Abstract
BACKGROUND: Hotspot mutations of the oncogenes BRAF and NRAS are the most common genetic alterations in cutaneous melanoma. Specific inhibitors of BRAF and MEK have shown significant survival benefits in large phase III trials. However, the prognostic significance of BRAF and NRAS mutations outside of clinical trials remains unclear.
Authors with CRIS profile
Involved external institutions
Klinikum der Universität München (Großhadern und Innenstadt)
Germany (DE)
Dresden International University GmbH (DIU)
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Germany (DE)
Dresden International University GmbH (DIU)
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
How to cite
APA:
Heppt, M.V., Siepmann, T., Engel, J., Schubert-Fritschle, G., Eckel, R., Mirlach, L.,... Berking, C. (2017). Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer, 17(1), 536-. https://doi.org/10.1186/s12885-017-3529-5
MLA:
Heppt, Markus V., et al. "Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care." BMC Cancer 17.1 (2017): 536-.
BibTeX: Download